NCT05335018

GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma

Active, enrolled Phase 2 Last updated 16 December 2024

What this trial tests

Phase 2 trial testing Glofitamab, Poseltinib, Lenalidomide in Relapsed/refractory Diffuse Large B Cell Lymphoma in 76 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

30 May 2022

Primary endpoint
30 November 2025

30 November 2026

Quick facts

Lead sponsor	Seoul National University Hospital
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	76
Start date	30 May 2022
Primary completion	30 November 2025
Estimated completion	30 November 2026
Sites	1 location across South Korea

Drugs / interventions tested

• Glofitamab, Poseltinib, Lenalidomide — full drug profile →

Conditions studied

• Relapsed/refractory Diffuse Large B Cell Lymphoma — all drugs for Relapsed/refractory Diffuse Large B Cell Lymphoma →

Sponsor

Seoul National University Hospital

Who can join

19 and older, any sex, with Relapsed/refractory Diffuse Large B Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, open-ended, single-arm, multicenter Phase II clinical trial. To evaluate the efficacy of Glofitamab, Poseltinib, and Lenalidomide combination therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Glofitamab: First Approval.
   Shirley M. · · 2023 · cited 41× · PMID 37285013 · DOI 10.1007/s40265-023-01894-5
2. Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial.
   Park C, Lee HS, Kang KW, Lee WS, et al · · 2024 · cited 9× · PMID 38555311 · DOI 10.1038/s41467-024-47198-4
3. The Evolving Role of Bispecific Antibodies in Diffuse Large B-Cell Lymphoma.
   Saleh K, Khoury R, Khalife N, Chahine C, et al · · 2024 · cited 8× · PMID 39063920 · DOI 10.3390/jpm14070666
4. Redefining Precision Management of r/r Large B-Cell Lymphoma: Novel Antibodies Take on CART and BMT in the Quest for Future Treatment Strategies.
   Dada R. · · 2023 · cited 7× · PMID 37508523 · DOI 10.3390/cells12141858
5. Bispecific Antibodies for Lymphoid Malignancy Treatment.
   Bisio M, Legato L, Fasano F, Benevolo Savelli C, et al · · 2024 · cited 4× · PMID 39796723 · DOI 10.3390/cancers17010094
6. New Frontiers in Monoclonal Antibodies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
   Schipani M, Rivolta GM, Margiotta-Casaluci G, Mahmoud AM, et al · · 2023 · cited 2× · PMID 38201614 · DOI 10.3390/cancers16010187
7. Bispecific Monoclonal Antibodies in Diffuse Large B-Cell Lymphoma: Dawn of a New Era in Targeted Therapy.
   Schipani M, Bellia M, Sella C, Dondolin R, et al · · 2025 · cited 1× · PMID 41097784 · DOI 10.3390/cancers17193258
8. Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma
   Cassanello G, Luna de Abia A, Falchi L. · · 2024